Taxiarchis V. Kourelis

Dr. Taxiarchis V. Kourelis

Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 June 2016 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
PDF file
AMAaron Mansfield
Aaron Mansfield
ATA. J. Tafur
A. J. Tafur
CWC. E. Wang
C. E. Wang
Taxiarchis V. KourelisTaxiarchis V. Kourelis
Taxiarchis V. Kourelis
EWE. M. Wysokinska
E. M. Wysokinska
PYP. Yang
P. Yang
Essentials Venous thromboembolism (VTE) prevention strategies require effective risk assessment models. We sought to validate the Khorana Risk Score (KRS) in patients with lung cancer. A high KRS was not predictive of VTE but was independently associated with all‐cause mortality. Our findings stress the need for a lung cancer‐specific VTE risk assessment model. Summary Objectives Lung cancer is strongly associated with venous thromboembolism (VTE), but primary prevention against VTE is not a validated management strategy. Risk assessment models will be necessary for efficient implementation of preventative strategies. Materials and methods Utilizing a prospectively collected lung cancer database, we aimed to validate the Khorana Risk Score (KRS) in the prediction of VTE among patients with lung cancer. VTE events were retrospectively identified by reviewers unaware of the clinical prediction score calculation. The association between KRS and the risk of VTE was examined using cumulative incidence function with competing risk models. Mortality prediction was evaluated as a secondary outcome. Results We included 719 patients in our review. The patients were predominantly older men with non‐small cell lung cancer and 40% had metastatic disease at inception. The median follow‐up was 15.2 months. There were 83 VTEs (11.5%) and 568 (78.8%) patients died. A high KRS (cumulative incidence, 12.4%; 95% confidence interval [CI], 6.4–20.5%) was not associated with VTE compared with an intermediate score (cumulative incidence, 12.1%; 95% confidence interval, 9.5–15.0%) in both univariate and multivariable analyses. However, a high KRS was a predictor of mortality (hazard ratio, 1.7; 95% CI, 1.4–2.2). Conclusions Among patients with lung cancer, the KRS did not stratify the patients at the highest risk of VTE. Improved risk stratification methods are needed for this group of patients prior to implementing a primary prevention strategy.

26 October 2021 in Leukemia
Verified
Journal Article
Closed access
PDF file
MBMoritz Binder
Moritz Binder
BNBharat Nandakumar
Bharat Nandakumar
SRS. Vincent Rajkumar
S. Vincent Rajkumar
PKPrashant Kapoor
Prashant Kapoor
FBFrancis K. Buadi
Francis K. Buadi
SKShaji K. Kumar
Shaji K. Kumar

21 April 2023 in Blood
Verified
Journal Article
Closed access
PDF file
FGFernanda Gutierrez-Rodrigues
Fernanda Gutierrez-Rodrigues
YKYael Kusne
Yael Kusne
JFJenna Fernandez
Jenna Fernandez
TLTerra L Lasho
Terra L Lasho
RSRuba N Shalhoub
Ruba N Shalhoub
MPMrinal M. Patnaik
Mrinal M. Patnaik
VEXAS is caused by somatic mutations in UBA1 (UBA1mut) and characterized by heterogenous systemic auto-inflammation and progressive hematologic manifestations, meeting criteria for myelodysplastic syndrome (MDS) and plasma cell dyscrasias. The landscape of myeloid-related gene mutations leading to typical clonal hematopoiesis (CH) in these patients is unknown. Retrospectively, we screened 80 VEXAS patients for CH in their peripheral blood (PB) and correlated findings with clinical outcomes in 77. UBA1mutwere most common at hotspot p.M41 (median variant allele frequency/VAF = 75%). Typical CH mutations co-occurred with UBA1mut in 60% of patients, mostly in DNMT3A and TET2, and were not associated with inflammatory or hematologic manifestations. In prospective single-cell proteogenomic sequencing (scDNA), UBA1mutwas the dominant clone, present mostly in branched clonal trajectories. Based on integrated bulk and scDNA analyses, clonality in VEXAS followed two major patterns: with either typical CH preceding UBA1mutselection in a clone (Pattern 1), or occurring as an UBA1mutsubclone or in independent clones (Pattern 2). VAF in PB differed markedly between DNMT3A and TET2 clones (median VAF of 25% vs 1%). DNMT3A and TET2 clones associated with hierarchies representing patterns 1 and 2, respectively. Overall survival for all patients was 60% at 10 years. Transfusion-dependent anemia, moderate thrombocytopenia, and typical CH mutations, each correlated with poor outcome. In VEXAS, UBA1mut cells are the primary cause of systemic inflammation and marrow failure, being a new molecularly defined somatic entity associated with MDS. VEXAS-associated MDS is distinct from classical MDS in its presentation and clinical course.

31 January 2022 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
NANadine H. Abdallah
Nadine H. Abdallah
MBMoritz Binder
Moritz Binder
SRS. Vincent Rajkumar
S. Vincent Rajkumar
PGPatricia T. Greipp
Patricia T. Greipp
PKPrashant Kapoor
Prashant Kapoor
SKShaji K. Kumar
Shaji K. Kumar
Risk stratification in multiple myeloma is important for prognostication, patient selection for clinical trials, and comparison of treatment approaches. We developed and validated a staging system that incorporates additional FISH abnormalities not included in the R-ISS and reflects the additive effects of co-occurring high-risk disease features. We first evaluated the prognostic value of predefined cytogenetic and laboratory abnormalities in 2556 Mayo Clinic patients diagnosed between February 2004 and June 2019. We then used data from 1327 patients to develop a risk stratification model and validated this in 502 patients enrolled in the MMRF CoMMpass study. On multivariate analysis, high-risk IgH translocations [risk ratio (RR): 1.7], 1q gain/amplification (RR: 1.4), chromosome17 abnormalities (RR: 1.6), ISS III (RR: 1.7), and elevated LDH (RR: 1.3) were independently associated with decreased overall survival (OS). Among 1327 evaluable patients, OS was 11.0 (95% CI: 9.2–12.6), 7.0 (95% CI: 6.3–9.2), and 4.5 (95% CI: 3.7–5.2) years in patients with 0 (stage I), 1 (stage II), and ≥2 (stage III) high-risk factors, respectively. In the MMRF cohort, median OS was 7.8 (95% CI: NR-NR), 6.0 (95% CI: 5.7-NR), and 4.3 (95% CI: 2.7-NR) years in the 3 groups, respectively (P < 0.001). This 5-factor, 3-tier system is easy to implement in practice and improves upon the current R-ISS.

4 August 2020 in Blood Advances
Verified
Journal Article
Open access
PDF file
NANadine Abdallah
Nadine Abdallah
PGPatricia Greipp
Patricia Greipp
PKPrashant Kapoor
Prashant Kapoor
MGMorie A. Gertz
Morie A. Gertz
ADAngela Dispenzieri
Angela Dispenzieri
SKShaji K. Kumar
Shaji K. Kumar
A gain in chromosome 1q (+1q) is among the most common cytogenetic abnormalities in multiple myeloma (MM). It is unclear whether +1q is independently associated with decreased overall survival (OS). The objective of this study was to evaluate the impact of +1q on clinical characteristics, treatment response, and survival outcomes. We included 1376 Mayo Clinic patients diagnosed with MM from 2005 to 2018 who underwent fluorescence in situ hybridization testing at diagnosis with a panel including the +1q probe. A gain in 1q was found in 391 patients (28%) and was associated with anemia, hypercalcemia, high tumor burden, International Staging System (ISS) stage 3, high-risk (HR) translocations, and chromosome 13 abnormalities. There was no difference in overall response or deeper responses to proteasome inhibitor (PI)–, immunomodulatory drug (iMiD)–, or PI plus IMiD–based induction. Time to next treatment was shorter in patients with +1q compared with those without +1q (19.9 vs 27.7 months; P < .001). On univariate analysis, +1q was associated with increased risk of death (risk ratio [RR], 1.9; P < .001), and decreased OS was seen in all treatment groups. +1q was independently associated with decreased OS on multivariate analysis when other HR cytogenetic abnormalities, ISS stage 3, and age ≥70 years were included (RR, 1.5; P < .001). Gain of >1 copy of 1q was not associated with worse OS compared with gain of 1 copy (4.9 vs 4.3 years; P = .21). +1q was associated with high tumor burden, advanced disease stage, and HR translocations. It is independently associated with decreased OS, even in the setting of novel therapy and transplant.

1 June 2021 in Mayo Clinic Proceedings
Verified
Journal Article
Closed access
EMEli Muchtar
Eli Muchtar
ADAngela Dispenzieri
Angela Dispenzieri
MGMorie A. Gertz
Morie A. Gertz
SKShaji K. Kumar
Shaji K. Kumar
FBFrancis K. Buadi
Francis K. Buadi
TSTaimur Sher
Taimur Sher